Skip to main content
Gubra A/S logo

Gubra A/S — Investor Relations & Filings

Ticker · GUBRA ISIN · DK0062266474 LEI · 254900T17RRFZONO6W53 CO Professional, scientific and technical activities
Open in API
Filings indexed 87 across all filing types
Latest filing 2026-05-11 Director's Dealing
Country DK Denmark
Listing CO GUBRA

About Gubra A/S

https://www.gubra.dk/

Gubra A/S is a biotechnology company and preclinical Contract Research Organization (CRO) specializing in peptide-based drug discovery. The company operates a dual business model, providing preclinical research services to pharmaceutical and biotech clients while also developing its own proprietary pipeline of therapeutics. Gubra's primary focus is on metabolic diseases, such as obesity, diabetes, and MASH (metabolic dysfunction-associated steatohepatitis), as well as fibrotic diseases. Its research and development activities also extend into inflammatory conditions, CNS, respiratory, and women's health. The CRO services division supports clients in advancing their drug development programs through expertise in areas like in vivo pharmacology and peptide chemistry.

Recent filings

Filing Released Lang Actions
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares
Director's Dealing Classification · 95% confidence The document is a regulatory press release under the Market Abuse Regulation disclosing share transactions by a board member (Niels Vrang) and a person closely associated with them. This is a classic insider trading notification. It fits the “Director’s Dealing” category (insider share transactions by company directors).
2026-05-11 English
AbbVie reports Positive Phase 1 Multiple Ascending Dose Results for ABBV-295, a Long-Acting Amylin Analog
Regulatory Filings Classification · 95% confidence The document is a regulatory press release issued by Gubra regarding clinical trial results for a drug (ABBV-295) developed in partnership with AbbVie. It details Phase 1 trial outcomes, including safety and efficacy data. As it is a general regulatory announcement regarding company operations and clinical progress that does not fit into specific categories like earnings releases or financial reports, it is classified as a Regulatory Filing (RNS).
2026-03-09 English
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares
Director's Dealing Classification · 100% confidence The document is a notification of a share transaction by a person discharging managerial responsibilities (PDMR), specifically a board member. It explicitly references the Market Abuse Regulation (MAR) article 19, which governs insider dealing and director transactions. This aligns perfectly with the definition of 'Director's Dealing' (DIRS).
2026-03-02 English
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares
Transaction in Own Shares Classification · 95% confidence The document consists solely of a detailed table listing dates, prices, and amounts, which appears to be a record of transactions or trades. There is no narrative text, no mention of financial results, management commentary, regulatory bodies, or report titles. The content is purely transactional data, likely representing trades or share transactions. Given the nature of the data, the most appropriate classification is 'Transaction in Own Shares' (POS), which covers reports of the company buying back or selling its own shares. The document length is sufficient and the content matches this category well.
2026-03-02 English
Annual Report 2025: A record year
Audit Report / Information Classification · 95% confidence The document is a regulatory press release from Gubra announcing their 2025 annual financial results. It provides key financial highlights, operational updates, and future outlooks, which are characteristic of an earnings release. While it mentions the 'Annual Report', the document itself is a summary press release (under 10,000 characters) rather than the full statutory annual report document. Therefore, it is classified as an Earnings Release. FY 2025
2026-02-27 English
Annual Report 2025: A record year
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2025' and contains comprehensive sections typical of an annual report, including management's review, financial statements, letter from the CEO and Chair, financial highlights, business strategy, ESG information, corporate governance, risk management, shareholder information, and detailed financial statements. The content covers the full fiscal year 2025, with detailed financial results, business unit descriptions, strategic outlook, and sustainability initiatives. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or summary. There is no indication that this is merely an announcement of the report or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2025
2026-02-27 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.